title: Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with acute myeloid leukemia.
abstract: The open-label, prospective study aimed to evaluate the efficacy and safety for standard intensive chemotherapy compared with attenuated therapy in elderly patients with acute myeloid leukemia (AML). A total of 297 patients between 65 and 82 years were enrolled in the study. The 141 patients received standard-dose therapy (daunorubicin 45 mg/m(2) × 3 days with cytarabine 100 mg/m(2) × 7 days for induction therapy, while post-induction therapy consisted of high-dose cytarabine 1.5 g/m(2) × 4 days), and the attenuated treatment (daunorubicin 30 mg/m(2) × 3 days with cytarabine 75 mg/m(2) × 7 days for induction therapy, while post-induction therapy consisted of attenuated high-dose Ara-C 1.0 g/m(2) × 3 days) was administered to the remaining 156 patients, based on a random number assigned. Total 168 patients (56.6%) achieved complete remission with an incomplete blood recovery (CR)/CRi. No significant differences were observed between the two treatments (P = 0.60). Attenuated chemotherapy improved overall survival (OS) and progression-free survival (PFS) compared to standard-dose therapy; 5-year OS values for these two groups were 39 and 24 months, respectively (P < 0.001), and the PFS values for these two groups were 35 versus 23 months (P < 0.001). In addition, the attenuated treatment with a poor risk profile overcame the negative impact and yielded OS and PFS values similar to those of the standard-dose chemotherapy with a better-to-intermediate risk profile. Five-year OS values for these two groups were 28 versus 28 months (P = 0.89), and the 5-year PFS values were 27 and 28 months, respectively (P = 0.89). The most common adverse drug effect for chemotherapy was agranulocytosis (98.3%). There was a significant difference in early mortality between the attenuated and standard-dose treatment groups (0.64% vs. 7.1%, respectively, P < 0.01). Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with AML.
authors.affiliation: Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, 1 TongDao Avenue North, Hohhot, 010059, People's Republic of China, huangbintao1979@sina.com.
authors.forename: Bin-Tao
authors.initials: BT
authors.lastname: Huang
authors.forename: Wei-Hong
authors.initials: WH
authors.lastname: Zhao
authors.forename: Qing-Chun
authors.initials: QC
authors.lastname: Zeng
authors.forename: Bing-Sheng
authors.initials: BS
authors.lastname: Li
authors.forename: Rui-lin
authors.initials: RL
authors.lastname: Chen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D003561:Cytarabine; D003630:Daunorubicin
references.citation: Blood. 2000 Sep 1;96(5):1670-3
references.pmid: 10961861
references.citation: N Engl J Med. 2009 Sep 24;361(13):1235-48
references.pmid: 19776405
references.citation: Blood. 2002 Oct 1;100(7):2292-302
references.pmid: 12239137
references.citation: Blood. 2006 May 1;107(9):3481-5
references.pmid: 16455952
references.citation: Curr Opin Oncol. 2009 Nov;21(6):589-93
references.pmid: 19812493
references.citation: Leuk Res. 2005 Jun;29(6):609-15
references.pmid: 15863199
references.citation: J Clin Oncol. 2003 Dec 15;21(24):4642-9
references.pmid: 14673054
references.citation: Int J Hematol. 2011 Apr;93(4):474-481
references.pmid: 21387092
references.citation: Leukemia. 2000 Mar;14(3):480-7
references.pmid: 10720146
references.citation: Ann Hematol. 2006 Jun;85(6):357-65
references.pmid: 16575580
references.citation: Oncology (Williston Park). 2000 Nov;14(11A):53-61
references.pmid: 11195419
references.citation: Blood. 2006 Jul 1;108(1):63-73
references.pmid: 16522815
references.citation: Leukemia. 2003 Aug;17(8):1521-8
references.pmid: 12886238
references.citation: Med Oncol. 2012 Mar;29(1):251-9
references.pmid: 21258877
references.citation: J Cancer Res Clin Oncol. 2012 Jan;138(1):125-32
references.pmid: 22057732
references.citation: Rev Clin Exp Hematol. 2002 Mar;6(1):46-59; discussion 86-7
references.pmid: 12060483
references.citation: Blood. 2007 Jun 15;109(12):5129-35
references.pmid: 17341661
references.citation: Ann Hematol. 2007 May;86(5):329-37
references.pmid: 17340137
references.citation: Leuk Res. 2012 Apr;36(4):407-12
references.pmid: 22325245
references.citation: N Engl J Med. 1994 Oct 6;331(14):896-903
references.pmid: 8078551
references.citation: Blood. 2001 Aug 1;98(3):548-53
references.pmid: 11468148
references.citation: Arch Intern Med. 2002 Jul 22;162(14):1597-603
references.pmid: 12123403